BioCryst Pharmaceuticals Inc (BCRX)

[conix]

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by stock analysts at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Monday, The Fly reports. They presently have a $13.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00. Barclays‘s price objective suggests a potential upside of 14.14% from the stock’s current price.

BCRX has been the subject of a number of other research reports. Piper Sandler restated an “in-line” rating and issued a $24.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 23rd. Evercore ISI lowered their target price on shares of BioCryst Pharmaceuticals from $25.00 to $15.00 in a research note on Friday, April 8th. StockNews.com assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Finally, Oppenheimer lowered their target price on shares of BioCryst Pharmaceuticals from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, April 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.09.